Introduction
============

Endoscopic submucosal dissection (ESD) for treating superficial colorectal neoplasms allows for en bloc resection of large tumors and accurate histopathological evaluations [@JR792-1] [@JR792-2] [@JR792-3] [@JR792-4] [@JR792-5] [@JR792-6] . However, colorectal ESD has a high adverse event (AE) frequency because of its technical difficulty and because of the thin walls, redundancy, and flexure of the colon [@JR792-5] [@JR792-7] [@JR792-8] [@JR792-9] [@JR792-10] . A major AE of colorectal ESD is perforation during the procedure, which can increase risk of peritonitis [@JR792-8] [@JR792-11] [@JR792-12] [@JR792-13] . Peritonitis can be prevented in instances of minor perforation by employing endoclips to close the defect [@JR792-13] . On the other hand, delayed perforation caused by transmural electrocautery burns may require emergency surgery. Moreover, transmural electrocautery burns after colorectal ESD may cause local peritonitis, resulting in abdominal pain and fever. Although these AEs can be managed by fasting and antibiotics, respectively, they result in longer hospitalization times and increased medical expenses [@JR792-14] .

Although prophylactic clip closure (PCC) of mucosal defects after colorectal endoscopic resection reduces the frequency of AEs [@JR792-14] [@JR792-15] [@JR792-16] [@JR792-17] ; few studies have reported the use of PCC following colorectal ESD. This study aimed to investigate the effectiveness of PCC of mucosal defects for AEs after colorectal ESD.

Patients and methods
====================

Patients
--------

This study was retrospective, single-center evaluation. Colorectal ESD was performed in 203 consecutive patients (217 lesions) at the New Tokyo Hospital between June 2010 and August 2016. The indication criteria for colorectal ESD were as follows; lesions with a depth of invasion limited to the mucosa or submucosa, lesions of \> 20 mm that were difficult to resect en bloc by endoscopic mucosal resection (EMR), recurrent lesions, and residual lesions with non-lifting sign [@JR792-18] [@JR792-19] . The exclusion criteria were cessation of the procedure due to severe fibrosis or difficulty in manipulating the endoscope. All patients included provided written informed consent before treatment. This study was approved by the Institutional Review Board of the New Tokyo Hospital (IRB No. NTH-0098).

ESD procedure
-------------

All colorectal lesions were initially evaluated using magnifying chromoendoscopy with crystal violet staining to determine whether ESD was indicated before treatment. ESD procedures were mainly performed by 3 ESD expert endoscopists (H. H., S. S., and S. T.) who have performed more than 300 gastric ESDs. Antibiotics (cefmetazole 1.0 g) were intravenously administered to all patients once a day before the procedure. All patients were intravenously sedated with 2 mg midazolam doses to perform colorectal ESD under conscious sedation. Additional doses of midazolam were administered as needed. The ESD procedure was performed using a single-channel endoscope (PCF-Q260AZI or GIF-Q240; Olympus, Tokyo, Japan). Following submucosal injection with sodium hyaluronate, a distal hemi-circumferential mucosal incision was made using FlushKnife BT (DK2618JB; Fujifilm, Tokyo, Japan) or Dual knife (KD-650L; Olympus, Tokyo, Japan). Next, a pocket was created in the submucosa to permit the endoscope to enter the submucosal layer for dissection. After submucosal dissection, the intact mucosa was cut using an electrosurgical knife. After tumor removal, if possible, we performed PCC. Complete PCC was defined as completely sutured the defect of the whole resection site using endoclips (ZEOCLIP ZP-CH; Zeon Medical INC., Tokyo, Japan) in a zipper fashion following colorectal ESD ( [Fig. 1](#FI792-1){ref-type="fig"} ), whereas incomplete PCC was defined as the mucosal defects that did not enable PCC or were partially sutured. If perforation occurred during colorectal ESD, the defect of the muscularis layer was closed with endoclips or the mucosal defect with perforation was completely sutured using endoclips, if possible.

![ Endoscopic submucosal dissection for a superficial colorectal neoplasia. **a** A laterally spreading tumor was identified at the sigmoid colon (approximately 2.5 × 2.5 cm). **b** A mucosal incision was performed. **c** Submucosal dissection was performed. **d** A mucosal defect after removal of the tumor. **e** Complete prophylactic clip closure (PCC) was performed for the mucosal defect in a zipper fashion. **f** The specimen was resected en bloc.](10-1055-s-0043-118743-i792ei1){#FI792-1}

The operation time was defined as the time from the submucosal injection to the completion of the operation. Submucosal fibrosis was defined as mild fibrosis or severe fibrosis on the basis of endoscopic findings when sodium hyaluronate was injected into the submucosal layer.

Definition of AEs
-----------------

For this study, four AEs following colorectal ESD were defined: delayed perforation, delayed bleeding, abdominal pain, and fever. Delayed perforation was defined as the presence of free or retroperitoneal air detected by abdominal radiography or abdominopelvic computed tomography after the completion of colorectal ESD if the patients had a sign of delayed perforation. Delayed bleeding was defined as overt hematochezia or melena arising from the resection site 4 hours to 28 days after the completion of colorectal ESD and/or requiring endoscopic hemostasis. Abdominal pain was defined at post-ESD clinical findings, such as sustained spontaneous pain or regional rebound tenderness, but without a frank perforation. Fever was defined as a body temperature of ≥ 37.5℃ that developed 4 hours to 3 days after colorectal ESD.

Data analysis
-------------

Included patients were categorized into 2 groups; a complete PCC group and an incomplete PCC group. To investigate the potential risk factors for AEs after colorectal ESD, we analyzed the following factors; age (\< 70 or ≥ 70 years), sex, hypertension, diabetes mellitus, liver cirrhosis, renal failure, cardiovascular disease, antithrombotic agents, location of the lesion (right side of colon, left side of colon, or rectum), macroscopic type (LST-G, LST-NG, or protruded type), tumor size (\< 40 or ≥ 40 mm), pathological findings (adenoma, intramucosal carcinoma, or carcinoma with submucosal invasion), fibrosis, incomplete PCC, operation time (\< 120 or ≥ 120 min), and perforation during ESD. Furthermore, we performed subgroup analysis among the resected specimen size of \< 40 mm to investigate the effect of PCC for AEs after colorectal ESD.

Statistical analysis
--------------------

Categorical variables were analyzed using the Fisher's exact test or the chi-squared test. Continuous variables were analyzed using the Mann-Whitney *U* test. A *P* value of \< 0.05 was considered statistically significant. Any variable found to be statistically significant in the univariate analyses was included in the multivariate logistic regression model. However, PCC was not included in the multivariate logistic regression model because of high correlation with the size of the resected specimens. All data analyses were conducted using the JMP statistical software for Windows, version 13.0 (SAS, Institute, Inc., Cary, NC, USA).

Results
=======

Baseline characteristics
------------------------

A total of 211 colorectal lesions were eligible for study inclusion. Six lesions were excluded because severe fibrosis required cessation of the procedure. Among 211 colorectal lesions, 123 lesions (58.3 %) underwent complete PCC (  [Fig. 2](#FI792-2){ref-type="fig"} ). [Table 1](#TB792-1){ref-type="table"} summarizes baseline characteristics and clinicopathological features of the 211 lesions. The mean age of the patients was 70.7 ± 9.2 years, and 124 of 211 lesions were male (58.8 %). The median tumor size was 27 mm, and the median operation time was 72 min.

![ Flowchart of inclusions and exclusions criteria for this study. ESD, Endoscopic submucosal dissection; PCC, prophylactic clip closure.](10-1055-s-0043-118743-i792ei2){#FI792-2}

###### Baseline characteristics and clinicopathological features of the colorectal ESD.

                                        **All lesions (n = 211)**
  ------------------------------------- ---------------------------
  Age, mean ± SD, y                      70.7 ± 9.2
  Sex (male), no. (%)                   124 (58.8)
  Hypertension, no. (%)                 119 (56.4)
  Diabetes mellitus, no. (%)             34 (16.1)
  Liver cirrhosis, no. (%)                8 (3.8)
  Renal failure, no. (%)                 13 (6.2)
  Cardiovascular disease, no. (%)        61 (28.9)
  Antithrombotic agents, no. (%)         59 (28.0)
  Location, no. (%)                     
  Right side of colon                   121 (57.3)
  Left side of colon                     47 (22.3)
  Rectum                                 43 (20.4)
  Macroscopic type, no. (%)             
  LST-G                                  89 (42.2)
  LST-NG                                108 (51.2)
  Protruded type                         14 (6.6)
  Tumor size, median (IQR), mm           27 (19 -- 34)
  Pathological findings, no. (%)        
  Adenoma                                78 (37.0)
  Intramucosal carcinoma                106 (50.2)
  Carcinoma with submucosal invasion     27 (12.8)
  Fibrosis, no. (%)                      72 (34.1)
  Complete PCC, no. (%)                 123 (58.3)
  En bloc resection, no. (%)            197 (93.4)
  Operation time, median (IQR), min      72 (46 -- 88)
  Hospitalization, median (IQR), days     4.7 (4 -- 5)
  Perforation during ESD, no. (%)         4 (1.9)
  AEs, no. (%)                           29 (13.7)
  Delayed perforation, no. (%)            0 (0)
  Delayed bleeding, no. (%)              12 (41.4)
  Fever, no. (%)                         12 (41.4)
  Abdominal pain, no. (%)                 2 (6.9)
  Fever and abdominal pain, no. (%)       2 (6.9)
  Delayed bleeding and fever, no. (%)     1 (3.4)

ESD, endoscopic submucosal dissection; SD, standard deviation; LST-G, laterally spreading tumors, granular type; LST-NG, laterally spreading tumors, nongranular type; IQR, interquartile range; PCC, prophylactic clip closure; AEs, adverse events.

There were 4 perforations during colorectal ESD (1.9 % \[4/211\]). Among them, the mucosal defects in 2 lesions were completely sutured using endoclips. For the other 2 lesions, although the defect of the muscularis layer due to perforation was closed with endoclips, the mucosal defects were left opened and not sutured. We categorized the former into the group with complete PCC and the latter into the group with incomplete PCC. All perforations were minor and were successfully managed conservatively.

Adverse events
--------------

AEs occurred in 29 of the 211 lesions (13.7 %). Delayed perforation was not observed in any patient. Twelve patients had delayed bleeding, 12 developed a fever, 2 had abdominal pain, 2 developed a fever and had abdominal pain, and 1 had delayed bleeding and fever (  [Table 1](#TB792-1){ref-type="table"} ). All bleeding events were successfully managed with endoscopic hemostasis, and fever and abdominal pain were successfully managed with antibiotics and fasting, respectively.

Analysis of AEs
---------------

To identify factors potentially influencing the frequency of AEs following ESD, we compared the group in which AEs occurred (n = 29) with the group in which no AEs occurred (n = 182) (  [Table 2](#TB792-2){ref-type="table"} ). Significant differences between the two groups were found with respect to tumor size ≥ 40 mm ( *P*  \< 0.001), presence of fibrosis ( *P*  = 0.005), incomplete PCC ( *P*  = 0.002), and operation time ≥ 120 mm ( *P*  = 0.004).

###### Comparison of the group with AEs and the group without AEs after colorectal ESD.

                                        **AEs (n = 29)**   **No AEs (n = 182)**   ***P* value**
  ------------------------------------- ------------------ ---------------------- ---------------
  Age ≥ 70 y, no. (%)                   21 (72.4)          102 (56.0)             0.108
  Sex (male), no. (%)                   16 (55.2)          108 (59.3)             0.689
  Hypertension, no. (%)                 15 (51.7)          104 (57.1)             0.688
  Diabetes mellitus, no. (%)             3 (10.3)           31 (17.0)             0.586
  Liver cirrhosis, no. (%)               3 (10.3)            5 (2.7)              0.081
  Renal failure, no. (%)                 3 (10.3)           10 (5.5)              0.395
  Cardiovascular disease, no. (%)        9 (31.0)           52 (28.6)             0.827
  Antithrombotic agents, no. (%)         8 (27.6)           51 (28.0)             \> 0.99
  Location, no. (%)                     0.236                                     
  Right side of colon                   16 (55.2)          105 (57.7)              
  Left side of colon                     4 (13.8)           43 (22.6)              
  Rectum                                 9 (31.0)           34 (18.7)              
  Macroscopic type, no. (%)             0.478                                     
  LST-G                                 15 (51.7)           74 (40.7)              
  LST-NG                                12 (41.4)           96 (52.7)              
  Protruded type                         2 (6.9)            12 (6.6)               
  Tumor size ≥ 40 mm, no. (%)           12 (41.4)           21 (11.5)             \< 0.001
  Pathological findings, no. (%)        0.142                                     
  Adenoma                                9 (31.0)           69 (37.9)              
  Intramucosal carcinoma                19 (65.5)           87 (47.8)              
  Carcinoma with submucosal carcinoma    1 (3.4)            26 (14.3)              
  Fibrosis, no. (%)                     17 (58.6)           55 (30.2)             0.005
  Incomplete PCC, no. (%)               20 (69.0)           68 (37.4)             0.002
  Operation time ≥ 120 min, no. (%)      8 (27.6)           14 (7.7)              0.004
  Perforation during ESD, no. (%)        2 (6.9)             2 (1.1)              0.092

AEs, adverse events; ESD, endoscopic submucosal dissection; LST-G, laterally spreading tumors, granular type; LST-NG, laterally spreading tumors, nongranular type; PCC, prophylactic clip closure.

Multivariate analysis with logistic regression was conducted to identify significant independent risk factors for post-ESD AEs ( [Table 3](#TB792-3){ref-type="table"} ). AEs had a higher likelihood of occurring in tumor size ≥ 40 mm (odds ratio \[OR\]: 3.91; 95 % confidence interval \[CI\]: 1.48 -- 10.40; *P*  = 0.006) and presence of fibrosis (OR: 3.29; 95 % CI: 1.41 -- 7.68; *P*  = 0.006). Operation time ≥ 120 min was not a significant risk factor for AEs occurrence.

###### Multivariate analysis with logistic regression for AEs after colorectal ESD.

                             **Odds ratio (95 % CI)**   ***P* value**
  -------------------------- -------------------------- ---------------
  Tumor size ≥ 40 mm         3.91 (1.48 -- 10.40)       0.006
  Fibrosis                   3.29 (1.41 -- 7.68)        0.006
  Operation time ≥ 120 min   2.51 (0.82 -- 7.68)        0.108

AEs, adverse events; ESD, endoscopic submucosal dissection; CI, confidence interval.

Analysis of PCC
---------------

Resected specimen size in the group with complete PCC had a tendency of being smaller size ( *P*  \< 0.001). The circumference of ESD ulcers in the group with complete PCC also presented a tendency of a smaller circumference ( *P*  \< 0.001). The frequency of AEs was significantly lower in the group with complete PCC than in the group with incomplete PCC (7.3 % \[9/123\] vs. 22.7 % \[20/88\]; *P*  \< 0.001). There were no significant differences between the 2 groups in terms of location and operation time ( [Table 4](#TB792-4){ref-type="table"} ). The mean number of endoclips used per defect was 5.4 (range: 3 -- 15).   [Table 5](#TB792-5){ref-type="table"} shows the correlation with AEs for resected specimen size \< 40 mm between the group with complete PCC and the group with incomplete PCC. There was no significant difference in AEs between the 2 groups (5.6 % \[6/107\] vs. 17.8 % \[8/45\]; *P*  = 0.069). Significant difference was observed between the 2 groups with regards to frequency of fever ( *P*  = 0.020), whereas no significant differences were observed for delayed bleeding and abdominal pain frequency ( [Table 5](#TB792-5){ref-type="table"} ).

###### Characteristics of patients between the group with complete PCC and the group with incomplete PCC.

                                         **Complete PCC (n = 123)**   **Incomplete PCC (n = 88)**   ***P* value**
  -------------------------------------- ---------------------------- ----------------------------- ---------------
  Location, no. (%)                                                                                 0.476
  Right side of colon                    71 (57.7)                    50 (56.8)                      
  Left side of colon                     30 (24.4)                    17 (19.3)                      
  Rectum                                 22 (17.9)                    21 (23.9)                      
  Resected specimen size, mm, no. (%)                                                               \< 0.001
  \< 30                                  65 (52.8)                    23 (26.1)                      
  30 -- 39                               42 (34.1)                    22 (25.0)                      
  40 -- 49                               12 (9.8)                     21 (23.9)                      
  50 -- 59                                2 (1.6)                     10 (11.4)                      
  60 -- 69                                2 (1.6)                      5 (5.7)                       
  \> 69                                   0 (0)                        7 (8.0)                       
  Circumference of ESD ulcers, no. (%)                                                              \< 0.001
  \< 1/4                                 88 (71.5)                    29 (33.0)                      
  \> 1/4, \< 1/2                         33 (26.8)                    49 (55.7)                      
  \> 1/2, \< 3/4                          1 (0.8)                     10 (11.4)                      
  \> 3/4                                  1 (0.8)                      0 (0)                         
  Operation time, median (IQR), min      58 (46 -- 82)                62 (40 -- 111)                0.552
  AEs, no. (%)                            9 (7.3)                     20 (22.7)                     \< 0.001

AEs, adverse events; PCC, prophylactic clip closure; ESD, endoscopic submucosal dissection; IQR, interquartile range.

###### The correlation with AEs for resected specimen size \< 40 mm between the group with complete PCC and the group with incomplete PCC.

                     **Complete PCC (n = 107)**   **Incomplete PCC (n = 45)**   **Odds ratio (95 % CI)**   ***P* value**
  ------------------ ---------------------------- ----------------------------- -------------------------- ---------------
  AEs, no. (%)       6 (5.6)                      8 (17.8)                      0.33 (0.09 -- 1.16)        0.069
  Delayed bleeding   3 (2.8)                      2 (4.4)                       0.62 (0.07 -- 7.70)        0.633
  Abdominal pain     1 (0.9)                      0 (0)                                                     \> 0.99
  Fever              3 (2.8)                      6 (13.3)                      0.19 (0.03 -- 0.94)        0.020

AEs, adverse events; PCC, prophylactic clip closure; CI, confidence interval.

Discussion
==========

We investigated the effectiveness of PCC of mucosal defects for AEs after colorectal ESD. Our findings suggested that tumor size and submucosal fibrosis were independent risk factors affecting frequency of AEs. AEs such as fever and abdominal pain after colorectal ESD could be the result of bacterial invasion from the mucosal defect or transmural burn syndrome, which is similar to postpolypectomy coagulation syndrome [@JR792-20] [@JR792-21] . A previous retrospective study reported that larger tumor size was significantly associated with post-ESD electrocoagulation syndrome [@JR792-21] . Similarly, in this study, multivariate analysis showed that tumor size was an independent risk factor for AEs after colorectal ESD. A larger tumor size requires frequent use of electrocautery for larger submucosal dissection, resulting in transmural burn.

Fibrosis is also an independent risk factor for AEs, such as a perforation, in colorectal ESD [@JR792-13] [@JR792-22] [@JR792-23] [@JR792-24] . In the current study, the frequency of fibrosis was significantly higher in the group with AEs than in the group without AEs. Furthermore, multivariate analysis showed that fibrosis was an independent risk factor for AEs following colorectal ESD. Frequent use of electrocautery with an electrosurgical knife due to submucosal fibrosis could cause excessive heating of the muscular layer, and transmural burn syndrome may be more likely to occur in patients with fibrosis than in those without fibrosis.

Previous retrospective studies have reported that PCC of mucosal defects after EMR and ESD significantly decreased the frequency of AEs, such as fever and abdominal pain [@JR792-14] [@JR792-15] . In this study, although the resected specimen size and circumference of ESD ulcers in the group with complete PCC had a tendency to be smaller than those in the group with incomplete PCC, univariate analysis of AEs in this study likewise found the frequency of AEs to be higher in the group with incomplete PCC. On the contrary, subgroup analysis of resected specimen \< 40 mm revealed that complete PCC did not decrease the frequency of AEs. However, the frequency of fever in the group with complete PCC was significantly lower than that in the group with incomplete PCC. Moreover, although 4 minor perforations occurred during colorectal ESD in this study, AEs occurred in 2 lesions with incomplete PCC for the mucosal defect; other 2 lesions with complete PCC had no AEs. The AEs in incomplete PCC were fever, and fever and abdominal pain. Gleaned from this study, ESD with complete PCC may have been effective in minimizing effects of perforation and AEs after colorectal ESD, especially the frequency of fever.

Regarding to delayed bleeding, reportedly, PCC after EMR or ESD decreases it [@JR792-14] [@JR792-15] . However, in this study, no significant difference was observed in the frequency of delayed bleeding in the subgroup analysis of resected specimen size of \< 40 mm between the group with complete PCC and the group with incomplete PCC. Two patients in the group with incomplete PCC had delayed bleeding after colorectal ESD. Among them, 1 patient was receiving antithrombotic agents, and the tumor location in the other patient was adjacent to the ileocecal valve. On the other hand, 3 patients in the group with complete PCC had delayed bleeding after colorectal ESD. All of these patients were receiving antithrombotic agents. It may be difficult to compare the difference with regard to delayed bleeding between the 2 groups, because the patients with delayed bleeding had some risks for the delayed bleeding, such as receiving antithrombotic agents and tumor location.

The current study had some limitations. First, it was a retrospective review of patients treated at a single institution. Moreover, this study had a sampling bias with regard to resected specimen size and circumference of ESD ulcers between the group with complete PCC and that with incomplete PCC. Second, the sample size of the group with AEs was comparatively small. Therefore, a further prospective, randomized study will be needed in the future.

Conclusion
==========

In conclusion, our data suggest that tumor size and submucosal fibrosis were independent risk factors for AEs after colorectal ESD. PCC may be effective in minimizing AEs after colorectal ESD, especially the frequency of fever.
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